Verve Therapeutics Inc 2025年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period endedMarch 31,2025OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934For the transition period from ____________ to ____________Commission File Number:001-40489 VERVE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) 82-4800132(I.R.S. EmployerIdentification No.) Delaware(State or other jurisdiction ofincorporation or organization) 201 Brookline Avenue,Suite 601Boston,Massachusetts(Address of principal executive offices) Registrant’s telephone number, including area code: (617)603-0070 Securities registered pursuant to Section 12(b) of the Act: TradingSymbol(s)VERV Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to filesuch reports), and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorterperiod that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, asmaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒ Accelerated filer☐Smaller reporting company☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of May 7, 2025, the registrant had89,143,237shares of common stock, par value $0.001 per share, outstanding. FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q includes forward-looking statements that involve substantial risks anduncertainties. All statements, other than statements of historical fact, contained in this Quarterly Report on Form 10-Q,including statements regarding our strategy, future operations, future financial position, future revenue, projected costs,prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,”“contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,”“should,” “target,” “will,” “would,” or the negative of these words or other similar expressions are intended to identifyforward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about: •the timing, progress, design and conduct of our ongoing Heart-2 clinical trial, a Phase 1b clinical trial of VERVE-102,and our ongoing Pulse-1 clinical trial, a Phase 1b clinical trial of VERVE-201, including statements regarding thetiming of enrollment and the period during which data or updates from such clinical trials is expected to becomeavailable; •the timing of initiation of the planned Phase 2 clinical trial of VERVE-102;•the timing for delivery of the opt-in package to Eli Lilly and Company, or Lilly, and Lilly's decision, and timing thereof,for the PCSK9 program;•our estimates regarding expenses, future revenue, capital requirements, need for additional financing and the periodover which we believe our existing cash, cash equivalents and marketable securities will be sufficient to fund ouroperating expenses and capital expenditure requirements;•the timing of and our ability to submit applications for and obtain and maintain regulatory approvals for our currentand future product candidates;•the potential therapeutic attributes and advantages of our current and future product candidates;•the timing, progress and conduct of our preclinical studies;•our expectations about the translatability of results from studies in animals into clinical trials in humans;•our plans to develop and, if approved, subsequently commercialize any product candidates we may develop;•the rate and degree of market acceptance and clinical utility of our products, if approved;•our estimates regarding the addressable patient population and potential market opportunity for our current andfuture product candidates;•our commercialization, marketing a